22,416 Shares in Gilead Sciences, Inc. $GILD Acquired by Csenge Advisory Group

Csenge Advisory Group acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 22,416 shares of the biopharmaceutical company’s stock, valued at approximately $2,832,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Paulson Wealth Management Inc. raised its stake in shares of Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after buying an additional 67 shares during the period. Essex Financial Services Inc. grew its stake in shares of Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 71 shares during the period. Davidson Trust Co. grew its stake in shares of Gilead Sciences by 4.1% during the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock worth $262,000 after acquiring an additional 74 shares during the period. Alpha Cubed Investments LLC increased its holdings in Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after acquiring an additional 75 shares during the last quarter. Finally, Financial Connections Group Inc. increased its holdings in Gilead Sciences by 30.2% in the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 76 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent research reports. Barclays dropped their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. HSBC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $133.00 to $155.00 in a research note on Monday, July 6th. Rothschild & Co Redburn dropped their price target on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a research note on Wednesday, August 5th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $158.04.

Gilead Sciences Stock Up 2.9%

Shares of NASDAQ GILD opened at $147.60 on Thursday. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company has a market cap of $183.02 billion, a P/E ratio of -55.28 and a beta of 0.32. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The business has a 50-day simple moving average of $131.21 and a two-hundred day simple moving average of $136.51.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. During the same period in the prior year, the business posted $2.01 earnings per share. The company’s revenue was up 10.6% on a year-over-year basis. Research analysts anticipate that Gilead Sciences, Inc. will post -0.53 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is -122.85%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating on Gilead, supporting the bullish view that the company’s recent momentum can continue. BMO Capital reaffirms Buy rating
• Positive Sentiment: Zacks Research raised estimates for third-quarter 2026 EPS to $1.93 from $1.84, fourth-quarter 2026 EPS to $2.14 from $2.07, and full-year 2027 EPS to $9.30 from $9.11. It also lifted estimates for parts of 2027, indicating improving expectations for near-term earnings. Gilead Sciences analyst estimates
• Positive Sentiment: Investors remain focused on Gilead’s expanding HIV portfolio. Biktarvy continues to anchor sales, while Yeztugo and additional pipeline programs could create new treatment and prevention opportunities. The company’s latest reported revenue also increased 10.6% year over year to $7.8 billion, exceeding expectations. Gilead’s expanding HIV portfolio
• Positive Sentiment: Gilead’s quarterly dividend of $0.82, equivalent to $3.28 annually, provides ongoing income support and reinforces its appeal to defensive and healthcare-focused investors.
• Neutral Sentiment: Zacks reduced estimates for first-quarter 2028 EPS to $2.14 from $2.21, second-quarter 2028 EPS to $2.27 from $2.33, and full-year 2028 EPS to $9.58 from $10.00. These cuts temper the otherwise positive near-term revisions and suggest some uncertainty about longer-term growth.
• Negative Sentiment: Chief Commercial Officer Johanna Mercier sold 28,000 shares, while CFO Andrew Dickinson sold 3,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may modestly weigh on sentiment.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the sale, the chief executive officer directly owned 592,133 shares in the company, valued at $77,160,851.23. This represents a 2.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the transaction, the insider directly owned 118,234 shares of the company’s stock, valued at approximately $16,273,727.76. The trade was a 19.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 82,000 shares of company stock valued at $10,837,860. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.